Orchard Therapeutics Announces Strategic Alliance with Oxford BioMedica

Orchard Therapeutics has announced that it has entered into a strategic alliance with Oxford BioMedica plc., a world-leading company in gene and cell therapy. Under the terms of the collaboration and licence agreement, Oxford BioMedica has granted an exclusive intellectual property licence to Orchard for collaboration programmes, and will provide process development services and manufacture […]

Read more

Amit Nathwani of Freeline Therapeutics has received an Outstanding Achievement Award from the European Society for Gene and Cell Therapy

Freeline Therapeutics announced that The European Society for Gene and Cell Therapy (EGCST) has recognised the Company’s Founder and Chief Scientific Officer (CSO), Professor Amit Nathwani, with the Outstanding Achievement Award. ESGCT seeks to honour one eminent scientist each year who has made pioneering research success and a significant and lasting contribution to the advancement of the […]

Read more

Achilles Therapeutics launched with funds of £13.2 million to develop immunotherapies for cancer

The UCL Technology Fund (UCLTF) announced its participation in the formation of Achilles Therapeutics Ltd, led by SYNCONA LLP and CANCER RESEARCH TECHNOLOGY (CRT). The new private company will bring together world-class research from UCL (University College London) and the Francis Crick Institute, funded by Cancer Research UK and the National Institute for Health Research (NIHR). […]

Read more

UCL Technology Fund highlighted at UCLB’s annual Summer Reception

The UCL Technology Fund, and its first Proof of Concept investment were highlighted at UCLB’s annual Summer Reception under the UCL portico this week. The evening was set against the backdrop of the neo-classical UCL Portico and the Flaxman Gallery. The event provided an informal networking opportunity for UCL’s researchers, guests of UCLB including representatives […]

Read more

Freeline Therapeutics acquires Munich-based manufacturing technology platform and has appointed Dr Markus Hörer as Chief Technology Officer

Freeline Therapeutics (“Freeline”), a biopharmaceutical company focused on the development of gene therapies for bleeding and other debilitating disorders, today announced the acquisition of the Adeno-Associated Virus (AAV) manufacturing platform developed by Rentschler Biotechnologie GmbH (Rentschler), a world leading contract manufacturer of biopharmaceuticals. In conjunction with the acquisition, Freeline has also established operations in Munich […]

Read more

UCLB and F-Prime launch Orchard Therapeutics to treat rare childhood diseases

Orchard Therapeutics launches with £21-million series A funding round UCL Business PLC (“UCLB”), the technology transfer company of University College London (“UCL”), and F-Prime Capital Partners have launched Orchard Therapeutics, a biotechnology company that will develop transformative gene therapies for life threatening orphan diseases. Orchard Therapeutics has secured £21-million in Series A financing led by […]

Read more

Albion to manage ground-breaking UCL Technology Fund

Albion Capital, one of the largest independent venture capital investors in the UK is to manage and administer the newly launched UCL Technology Fund, (“the Fund”), which has raised £50 million to commercialise University College London’s (“UCL”) world-class research output. Albion will manage and administer the Fund in partnership with UCL’s technology transfer company UCL […]

Read more